propafenone has been researched along with Myocardial Ischemia in 12 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral propafenone hydrochloride effect was studied on atrial signal-averaged ECG (ASAECG) during time- and frequency-domain analysis in patients with paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD)." | 9.08 | [Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. ( Banasiak, W; Fuglewicz, A; Kałka, D; Lacheta, W; Molenda, W; Pieróg, M; Ponikowski, P; Telichowski, A; Wiech, K; Zebrowski, J, 1995) |
| "During myocardial ischemia, particularly during LAD occlusion, propafenone results in a significant increase in QT dispersion." | 9.08 | Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study. ( Daisenberger, K; Faber, TS; Just, H; Krahnefeld, O; Meinertz, T; Zehender, M, 1997) |
| "Propafenone is a potent antiarrhythmic agent effective in either supraventricular or ventricular tachyarrhythmias." | 8.79 | Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. ( Boriani, G; Capucci, A, 1995) |
| "Oral propafenone hydrochloride effect was studied on atrial signal-averaged ECG (ASAECG) during time- and frequency-domain analysis in patients with paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD)." | 5.08 | [Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. ( Banasiak, W; Fuglewicz, A; Kałka, D; Lacheta, W; Molenda, W; Pieróg, M; Ponikowski, P; Telichowski, A; Wiech, K; Zebrowski, J, 1995) |
| "During myocardial ischemia, particularly during LAD occlusion, propafenone results in a significant increase in QT dispersion." | 5.08 | Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study. ( Daisenberger, K; Faber, TS; Just, H; Krahnefeld, O; Meinertz, T; Zehender, M, 1997) |
| "Propafenone is a potent antiarrhythmic agent effective in either supraventricular or ventricular tachyarrhythmias." | 4.79 | Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. ( Boriani, G; Capucci, A, 1995) |
| " In 11 dogs the effects of myocardial ischemia, premature epicardial stimulation (PES) and propafenone on anisotropic conduction properties were tested using three-dimensional mapping techniques." | 3.72 | Effects of acute ischemia, early extrabeats and propafenone on complex activation patterns in intact and ischemic canine hearts. ( Bauer, A; Becker, R; Kraft, P; Kuebler, W; Schoels, W; Schreiner, KD; Senges, JC; Voss, F, 2003) |
| "Amiodarone has a more favourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heart failure." | 2.67 | A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). ( , 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (75.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lip, GY | 1 |
| Fauchier, L | 1 |
| Freedman, SB | 1 |
| Van Gelder, I | 1 |
| Natale, A | 1 |
| Gianni, C | 1 |
| Nattel, S | 1 |
| Potpara, T | 1 |
| Rienstra, M | 1 |
| Tse, HF | 1 |
| Lane, DA | 1 |
| Bauer, A | 1 |
| Becker, R | 1 |
| Voss, F | 1 |
| Senges, JC | 1 |
| Kraft, P | 1 |
| Schreiner, KD | 1 |
| Kuebler, W | 1 |
| Schoels, W | 1 |
| Ye, VZ | 1 |
| Wyse, KR | 1 |
| Campbell, TJ | 1 |
| Palazzuoli, V | 2 |
| Mondillo, S | 2 |
| Faglia, S | 2 |
| D'Aprile, N | 2 |
| Camporeale, A | 1 |
| Gennari, C | 1 |
| Capucci, A | 1 |
| Boriani, G | 1 |
| Aupetit, JF | 1 |
| Timour, Q | 1 |
| Larbre, JP | 1 |
| Loufoua-Moundanga, J | 1 |
| Kioueh, I | 1 |
| Lopez, M | 1 |
| Faucon, G | 1 |
| Telichowski, A | 1 |
| Banasiak, W | 1 |
| Ponikowski, P | 1 |
| Wiech, K | 1 |
| Zebrowski, J | 1 |
| Pieróg, M | 1 |
| Kałka, D | 1 |
| Lacheta, W | 1 |
| Fuglewicz, A | 1 |
| Molenda, W | 1 |
| Mangiacotti, L | 1 |
| Campolo, MA | 1 |
| Agricola, E | 1 |
| Faber, TS | 1 |
| Zehender, M | 1 |
| Krahnefeld, O | 1 |
| Daisenberger, K | 1 |
| Meinertz, T | 1 |
| Just, H | 1 |
| Pelter, MM | 1 |
| Adams, MG | 1 |
| Nakamura, T | 1 |
| Kashimoto, S | 1 |
| Oguchi, T | 1 |
| Kumazawa, T | 1 |
2 reviews available for propafenone and Myocardial Ischemia
| Article | Year |
|---|---|
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Electrophysiology; Female; | 1995 |
5 trials available for propafenone and Myocardial Ischemia
| Article | Year |
|---|---|
[The evaluation of the antiarrhythmic activity of L-carnitine and propafenone in ischemic cardiopathy].
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Carnitine; Drug Therapy, Combination; El | 1993 |
[Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography; Electrocar | 1995 |
[Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Carnitine; Drug Sy | 1995 |
Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Double-Blind Method; Electrocardiography; Female; Heart Conduct | 1997 |
A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.).
Topics: Amiodarone; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; | 1992 |
5 other studies available for propafenone and Myocardial Ischemia
| Article | Year |
|---|---|
Effects of acute ischemia, early extrabeats and propafenone on complex activation patterns in intact and ischemic canine hearts.
Topics: Animals; Anisotropy; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Elect | 2003 |
Lidocaine shows greater selective depression of depolarized and acidotic myocardium than propafenone: possible implications for proarrhythmia.
Topics: Action Potentials; Analysis of Variance; Animals; Arrhythmias, Cardiac; Female; Guinea Pigs; Heart; | 1993 |
Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia--study in the porcine in situ heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 1993 |
Giant inverted T waves.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Humans; Male; Myocardial Is | 2001 |
Effects of propafenone on function and metabolism in the ischemic working rat heart.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Energy Metabolism; Heart Rate; Hemodynamics; Male; | 1992 |